Literature DB >> 21540889

RAF-isotype switching: from B to C through PDE.

Eric Lau, Ze'ev Ronai.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21540889      PMCID： PMC4560464          DOI： 10.1038/nsmb.2063

Source DB:  PubMed          Journal:  Nat Struct Mol Biol        ISSN： 1545-9985            Impact factor:   15.369


× No keyword cloud information.
  28 in total

Review 1.  Genetics of melanoma predisposition.

Authors:  Nicholas K Hayward
Journal:  Oncogene       Date:  2003-05-19       Impact factor: 9.867

2.  Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A.

Authors:  Imanol Arozarena; Berta Sanchez-Laorden; Leisl Packer; Cristina Hidalgo-Carcedo; Robert Hayward; Amaya Viros; Erik Sahai; Richard Marais
Journal:  Cancer Cell       Date:  2011-01-06       Impact factor: 31.743

3.  Melanoma and viagra: an unexpected connection.

Authors:  Devarati Mitra; Kathleen C Robinson; David E Fisher
Journal:  Pigment Cell Melanoma Res       Date:  2011-02       Impact factor: 4.693

4.  Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib.

Authors:  Jean Philippe Arnault; Janine Wechsler; Bernard Escudier; Alain Spatz; Gorana Tomasic; Vincent Sibaud; Selim Aractingi; Jean-Didier Grange; Vichnou Poirier-Colame; David Malka; Jean-Charles Soria; Christine Mateus; Caroline Robert
Journal:  J Clin Oncol       Date:  2009-07-13       Impact factor: 44.544

5.  In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling.

Authors:  Nicolas Dumaz; Robert Hayward; Jan Martin; Lesley Ogilvie; Douglas Hedley; John A Curtin; Boris C Bastian; Caroline Springer; Richard Marais
Journal:  Cancer Res       Date:  2006-10-01       Impact factor: 12.701

6.  Hyperactivation of MEK-ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells.

Authors:  F M Kaplan; Y Shao; M M Mayberry; A E Aplin
Journal:  Oncogene       Date:  2010-09-06       Impact factor: 9.867

Review 7.  Targeting cancer with phosphodiesterase inhibitors.

Authors:  Rajkumar Savai; Soni Savai Pullamsetti; Gamal-Andre Banat; Norbert Weissmann; Hossein Ardeschir Ghofrani; Friedrich Grimminger; Ralph Theo Schermuly
Journal:  Expert Opin Investig Drugs       Date:  2010-01       Impact factor: 6.206

Review 8.  G-protein-coupled receptors and melanoma.

Authors:  Hwa Jin Lee; Brian Wall; Suzie Chen
Journal:  Pigment Cell Melanoma Res       Date:  2008-05-27       Impact factor: 4.693

Review 9.  Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.

Authors:  David Montani; Marie-Camille Chaumais; Laurent Savale; Delphine Natali; Laura C Price; Xavier Jaïs; Marc Humbert; Gérald Simonneau; Olivier Sitbon
Journal:  Adv Ther       Date:  2009-09-19       Impact factor: 3.845

10.  Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma.

Authors:  Clara Montagut; Sreenath V Sharma; Toshi Shioda; Ultan McDermott; Matthew Ulman; Lindsey E Ulkus; Dora Dias-Santagata; Hannah Stubbs; Diana Y Lee; Anurag Singh; Lisa Drew; Daniel A Haber; Jeffrey Settleman
Journal:  Cancer Res       Date:  2008-06-15       Impact factor: 12.701
View more
  1 in total

1.  Phosphodiesterase 4 regulates the migration of B16-F10 melanoma cells.

Authors:  Yoshihiro Watanabe; Taku Murata; Kasumi Shimizu; Hiroshi Morita; Madoka Inui; Toshiro Tagawa
Journal:  Exp Ther Med       Date:  2012-05-23       Impact factor: 2.447
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.